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Abstract
Background: Circulating follicular helper T (Tfh) cells are a heterogeneous population of CD4+ helper T cells that
promotes pathogenic immune responses in autoimmune diseases. In this study, we examined the status of
different subpopulations of Tfh cells in peripheral circulation and their associations with various clinical
characteristics of IgA vasculitis (IgAV).
Methods: According to the phenotypic expressions of different molecules, focus was given on six subpopulations
of Tfh cells: CD4+CXCR5+, CD4+CXCR5+ICOS+, CD4+CXCR5+ICOS+PD-1+, CD4+CXCR5+ICOShighPD-1high, CD4+CXCR5+
ICOS−PD-1+, and CXCR5+CD45RA−IL-21+. The frequencies of these six subpopulations and the circulating level of
Tfh-related cytokine interleukin 21 (IL-21) were measured from 27 patients with IgAV and 15 healthy controls (HC)
by flow cytometry and flow cytometric bead array, respectively.
Results: Significantly higher frequencies of CD4+CXCR5+, CD4+CXCR5+ICOS+, CD4+CXCR5+ICOS+PD-1+, CD4+CXCR5+
ICOShighPD-1high and CXCR5+CD45RA−IL-21+ Tfh cells, as well as higher levels of plasma IL-21, were detected in IgAV
patients compared to HC. The level of each Tfh subpopulation varied by the presenting symptoms of IgAV, but did not
differ between patients treated or not treated with glucocorticoids. When the disease entered the remission stage
following treatment, circulating levels of CD4+CXCR5+, CD4+CXCR5+ICOS+, CD4+CXCR5+ICOS+PD-1+, CD4+CXCR5+
ICOShighPD-1high and CXCR5+CD45RA−IL-21+ Tfh cells, as well as plasma IL-21 levels were reduced. Among the six
subpopulations of Tfh cells, both CD4+CXCR5+ICOS+ and CXCR5+CD45RA−IL-21+ significantly and positively correlated
with serum IgA and plasma IL-21 levels, but only CXCR5+CD45RA−IL-21+ significantly and negatively correlated with
the serum C4 level.
Conclusions: Tfh cells may differentially contribute to the development of IgAV or predict disease progression. These
findings provide novel insights in the pathogenesis of IgAV and may benefit treatment development targeting organ-
specific presenting symptoms of IgAV.
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Background
Immunoglobulin A vasculitis (IgAV), also known as
Henoch-Schönlein purpura, is an autoimmune disease
caused by the deposition of IgA-dominant immune com-
plexes in small vessels [1, 2]. It is the most common
cutaneous vasculitis in children, and its annual incidence
is 13–20 per 100,000 children under 17 years old [3].
IgAV usually develops following the upper respiratory
infection of viruses, bacteria, parasites, or others; with
the common ones being group A streptococci, Myco-
plasma, Epstein-Barr virus, Varicella virus and others [4].
The clinical features of IgAV are characterized by a tet-
rad of non-thrombocytopenic palpable purpura (most
commonly located on the lower extremities and but-
tocks, skin involvement), arthralgia/arthritis (joint in-
volvement), bowel angina (gastrointestinal involvement),
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and hematuria/proteinuria (renal involvement) [5]. Ther-
apy for IgAV is mostly supportive and symptomatic, be-
cause the disease is usually benign and self-limited. For
patients with severe active symptoms in one or multiple
organs, glucocorticoids (GC) are administered to im-
prove the treatment effect. Complications are rare. How-
ever, complications resulting from blood vessel lesions in
different organ systems could sometimes be severe, of
which, renal involvement is the most serious complication
and the principle cause of mortality in IgAV patients [6–8].
Although the pathogenesis of IgAV is not completely
understood, it is clear that both the aberrant deposition
of glycosylated IgA in small vascular walls and the sub-
sequent activation of an alternate complement pathway
play a central role in IgAV development [9]. Multiple
immune cell types including CD4+ helper T (Th) cells, B
cells and natural killer (NK) cells are implicated in the
pathogenesis of IgAV [10]. Furthermore, Th1/Th2 imbal-
ance, the hyperactivity of Th2 cells and the decline in
the ratio of CD4+/CD8+ cells increase the synthesis and
release of immunoglobulins in IgAV patients. The in-
creased frequency of peripheral Th17 cells and serum
IL-17 levels were also observed in childhood IgAV [11].
Follicular helper T (Tfh) cells are a subset of CD4+ Th
cells that are specialized in helping B cell responses to
produce antigen-specific antibodies such as IgA, IgE,
IgG and IgM in autoimmune diseases, infectious dis-
eases, and tumors [12–14]. Although no unique markers
have been reported for Tfh cells, they could be identified
through a combination of markers closely related to
their functions including chemokine receptor CXCR5,
programmed death-1 (PD-1), inducible costimulator
(ICOS), SLAM adapter protein (SAP), B and T lympho-
cyte attenuator (BTLA), CD40 ligand (CD40L) and cyto-
kine interleukin 21 (IL-21). Originally identified in
germinal centers of secondary lymphoid organs and es-
sential for germinal center formation, B-cell affinity mat-
uration, class switch recombination, and the generation
of plasma and memory B cells [15–17], Tfh counterparts
were recently detected in tonsils [18] and blood circula-
tions [19, 20]. The expansion of circulating Tfh cells has
been reported in various autoimmune diseases [19, 21],
suggesting their pathogenic significance. Xie et al. re-
vealed that the frequency of circulating CD4+CXCR5
+ICOS+ Tfh cells in children with active IgAV was sig-
nificantly higher than in healthy children [22]. Wang et
al. also reported that the upregulation of circulating Tfh
cells and downregulation of circulating follicular regula-
tory T (Tfr) cells may contribute to the pathogenesis of
IgAV in children [23]. At present, many questions re-
main to be addressed in regard to the expansion of cir-
culating Tfh cells in autoimmune diseases. When Tfh
cells are characterized by common markers, are we
obtaining a homogenous or heterogeneous population of
Tfh cells? If Tfh cells are composed of heterogeneous
subpopulations, as suggested by other studies [20], is
each subpopulation functionally equivalent in the patho-
genesis of a specific autoimmune disease? The answers
to these questions would improve our understanding
not only on Tfh cells and their functions, but also on
their specific contribution to autoimmune diseases,
which would facilitate therapeutic development.
In order to address these questions, in this study, we
focused on six phenotypic subpopulations of circulating
Tfh cells as defined by the expressions of distinct mole-
cules, examined their associations with IgAV, specifically
the different dominant symptoms presented in IgAV,
and explored the correlations between these Tfh subpop-
ulations and key IgAV clinical parameters.
Methods
Patients
The experimental protocols were established following
the Declaration of Helsinki and approved by the Human
Ethics Committee of Jilin University (Changchun,
China). Written informed consent was obtained from all
participants. A total of 27 patients with newly diagnosed
active IgAV admitted to the inpatient care of the Depart-
ment of Pediatrics, the First Hospital of Jilin University
from September 2014 to September 2015 were recruited
into this study. All patients met the following criteria:
(1) children under 18 years, (2) confirmed diagnosis of
IgAV according to the European League Against
Rheumatism/ Pediatric Rheumatology International Tri-
als Organization/ Pediatric Rheumatology European So-
ciety (EULAR/PRINTO/PRES) criteria [24], and (3)
patients without other autoimmune diseases. The de-
tailed EULAR/PRINTO/PRES diagnostic criteria are as
follows: the presence of palpable purpura (mandatory
criterion), together with at least one of following
findings: (1) diffuse abdominal pain (abdominal involve-
ment); (2) histopathology characterized by typical
leukocytoclastic vasculitis (LCV) with predominant IgA
deposits or proliferative glomerulonephritis with pre-
dominant IgA deposits; (3) acute arthritis or arthralgia
(joint involvement); (4) renal involvement manifested by
proteinuria (>0.3 g/24 h or >30 mmol/mg of urine
albumin/creatinine ratio from the first morning urine
sample), and/or hematuria (red blood cell [RBC] casts
with >5 red blood cells/high-power field or ≥2+ on
dipstick or presence of RBC casts in urinary sediment).
According to presenting symptoms, the 27 patients in
this study were further divided into five groups: skin
type (n = 8), abdominal type (n = 8), kidney type (n = 5),
joint type (n = 3) and the mixed type (patients presenting
two or more non-purpura symptoms, n = 3).
Due to the self-limited and benign course of IgAV,
symptom-oriented and supportive therapies were
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administered to patients following admission. For patients
that presented severe gastrointestinal complications or pro-
liferative glomerulonephritis, GC (intravenous methylpred-
nisolone treatment starting at 3–5 mg/kg body weight/day,
followed by tapering dosages until the relief of symptoms)
were administered. Following treatment, remission was de-
fined as the satisfaction of the following two criteria: (1)
after 5–7 days of treatment, all skin purpura became obvi-
ously shallow or completely subsided, and no new rash ap-
peared; (2) children with intestinal wall edema, arthralgia,
hematuria and/or proteinuria, and other related symptoms
experienced a dramatic relief of symptoms.
As controls, 15 age- and gender-matched healthy indi-
viduals (healthy controls, HC) were recruited into this
study. Upon recruitment, the following clinical parame-
ters were measured on all participants: routine blood
test, serum immunoglobulin and complement level (by a
specific protein analyzer SIEMENS BN-II, Germany),
serum C-reactive protein (CRP) (using the QuikRead go
CRP kit, Orion Diagnostica, Finland), urinary protein
(using a P800 Biochemical Analyzer, Roche, Germany),
and urinary RBC and white blood cell (WBC) count
(using a UF-1000 automatic urine sediment analyzer,
Sysmex, Japan).
Cell isolation
Fasting venous blood samples were collected from HC
and IgAV patients upon admission, and after disease re-
mission (for IgAV patients only), respectively. Peripheral
blood mononuclear cells (PBMCs) were isolated from in-
dividual patients and HC by density-gradient centrifuga-
tion using Ficoll-Paque Plus (Amersham Biosciences,
Little Chalfont, UK) at 800 × g for 30 min at 25 °C.
Flow cytometry analysis
Freshly isolated PBMCs (4 × 106/mL) were cultured in
10 % fetal calf serum RPMI-1640 (Hyclone, Logan, UT,
USA) in U-bottom 24-well tissue culture plates (Costar,
Lowell, MA, USA), stimulated with or without 50 ng/
mL of phorbol myristate acetate (PMA) plus 2 μg/mL of
ionomycin (Sigma, St. Louis, MO, USA) for one hour,
followed by treatment with Brefeldin A (10 μg/mL,
GolgiStop™; BD Biosciences, San Jose, CA, USA) for an
additional five hours. Then, these cells were stained in
duplicate with BV510-anti-CD3, APC-H7-anti-CD4,
BB515-anti-CXCR5, PE-Cy5-anti-CD45RA, PE-CF594-
anti-CD279 and BV421-anti-CD278 (Beckton Dickinson,
San Jose, CA, USA) at room temperature for 30 min.
Subsequently, cells were fixed, permeabilized, and
stained with PE-anti-IL-21 (Beckton Dickinson). The fre-
quencies of distinct Tfh cells were analyzed by multi-
color flow cytometry (FACSAria™ II, BD Biosciences),
and data were processed using FlowJo software (v5.7.2;
FlowJo, Ashland, OR, USA).
Measurement of plasma IL-21 by cytometric bead array
(CBA)
Plasma IL-21 concentrations were determined by a CBA
human soluble protein master buffer kit (BD Biosci-
ences) according to the manufacturer’s instructions,
analyzed using a flow cytometer (FACSAria™ II, BD Bio-
sciences), and quantified using the CellQuest Pro and
CBA software (Becton Dickinson).
Statistical analysis
Overall variations among the different groups were ana-
lyzed by one-way ANOVA. All data were presented as
median and range. Student’s unpaired or paired t-test
was appropriately chosen between groups. Mann–
Whitney test was performed for nonparametric data
between the two studied groups. The relationship be-
tween variables was analyzed by Pearson rank correl-
ation test. All statistical analyses were performed
using SPSS version 19.0 software. A two-tailed P
value <0.05 was considered statistically significant.
Results
Clinical characteristics of children with IgAV
The general demographic and clinical characteristics of
all participants are summarized in Table 1. According to
the presenting symptoms, eight patients (29.63 %) pre-
sented with skin purpura (skin type), eight (29.63 %)
with gastrointestinal tract discomfort (abdominal type),
five (18.52 %) with microhematuria and/or mild protein-
uria (1+ to 2+) (kidney type), three (11.1 %) with arthral-
gia and/or arthritis (joint type), and three (11.11 %) with
two or more non-purpura symptoms (mixed type). Pre-
ceding upper airway infections were recorded in 20
(74.07 %) patients, and 23 (85.19 %) patients were tested
positive for mycoplasma infection. Upon recruitment,
the WBC count (P < 0.0001), platelet (P = 0.0045), serum
IgA (P = 0.0097), IgE (P = 0.0371) and complement C4
(P = 0.0476) levels were significantly higher in IgAV pa-
tients than in HC (Table 1).
Detection of circulating Tfh cells
In order to assess the significance of circulating Tfh
cells in IgAV, focus was given on the following Tfh
cells: CD4+CXCR5+, CD4+CXCR5+ICOS+, CD4+CXCR5+
ICOS+PD-1+, CD4+CXCR5highICOS+PD-1high, CD4+
CXCR5+ICOS−PD-1+, and CXCR5+CD45RA−IL-21+,
which were identified by flow cytometry (Fig. 1).
CD4+CXCR5+ Tfh cells and its four subpopulations,
CD4+CXCR5+ICOS+, CD4+CXCR5+ICOS+PD-1+, CD4+
CXCR5+ICOShighPD-1high and CD4+CXCR5+ICOS−PD-1+,
were gated from CD3+CD4+ T cells (Fig. 1a); while
CXCR5+CD45RA−IL-21+ Tfh cells were independently
gated from CD3+CD4+ T cells (Fig. 1b).
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Association of different phenotypic subpopulations of Tfh
cells and cytokine with IgAV symptoms and treatment
options
Next, we analyzed the status of different subpopulations
of Tfh cells and plasma Tfh cytokine IL-21 in IgAV,
as well as their associations to IgAV symptoms and
treatments.
The frequencies of circulating CD4+CXCR5+ (data
were not shown), CD4+CXCR5+ICOS+, CD4+CXCR5+
ICOS+PD-1+, CD4+CXCR5highICOS+PD-1high and CXCR5+
CD45RA−IL-21+ Tfh cells, as well as plasma IL-21 levels,
were all significantly higher in IgAV patients than in
HC (P < 0.05; Fig. 2); while the frequency of circulat-
ing CD4+CXCR5+ICOS−PD-1+ was not significantly
different between these two groups (P > 0.05; Fig. 2).
Further analysis on the association of circulating Tfh
cells or plasma IL-21 levels with the presenting symp-
toms of IgAV revealed different patterns of association
(Fig. 2b): compared to levels in HC, CD4+CXCR5+ Tfh
cells were significantly higher in patients with skin,
kidney, joint and mixed types (P = 0.0069, 0.0233, 0.0236
Table 1 The demographic and clinical characteristics of
participants
IgAV (n = 27) Healthy Controls (n = 15)
Age, year 7 (3–13) 6 (2–14)
Female/Male 14/13 7/8
WBC, 109/L 9.32 (4.23–19.33)* 7.5 (5.31–9.28)
Lymphocytes, 106/L 3.96 (1.1–5.54) 3.57 (1.46–4.07)
Platelet, g/L 303 (188–463)* 298 (172–404)
Serum IgA, g/L 2.14 (0.95–5.91)* 1.47 (0.91–4.03)
Serum IgG, g/L 10.5 (0.95–17.4) 9.28 (1.03–15.22)
Serum IgM, g/L 1.18 (0.7–3.22) 1.07 (0.65–3.51)
Serum IgE, g/L 54.6 (16.7–657)* 22.1 (17.1–77.4)
Serum C3, g/L 1.29 (0.89–1.63) 1.35 (0.91–1.68)
Serum C4, g/L 0.34 (0.18–0.45)* 0.23 (0.16–0.41)
Serum CRP (mg/L) 7.23 (1.16–72.54)* 3.5 (0.82–5.1)
*P < 0.05, vs HC the values before treatment
Fig. 1 Detection of circulating Tfh cells by flow cytometry. PBMCs were isolated from IgAV patients (n = 27) and age- and gender-matched
healthy controls (HC; n = 15), stained with fluorophore-conjugated antibody targeting indicated proteins, and analyzed by flow cytometry. a The
gating strategy to identify CD4+CXCR5+, CD4+CXCR5+ICOS+, CD4+CXCR5+ICOS+PD-1+, CD4+CXCR5+ICOShighPD-1high, and CD4+CXCR5+ICOS−PD-1+
Tfh cells. b The gating strategy to identify CXCR5 + CD45RA-IL-21+ Tfh cells
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and 0.0494, respectively), but not in those with abdom-
inal type (P > 0.05, data were not shown); CD4+CXCR5+
ICOS+ Tfh cells increased in patients with abdominal,
kidney and mixed types (P = 0.0060, 0.0007 and 0.0005,
respectively), but not in those with skin or joint type
(P > 0.05); both CD4+CXCR5+ICOS+PD-1+ and CD4+
Fig. 2 Association of different phenotypes of Tfh cells with IgAV symptoms and treatment options. The comparison of indicated Tfh cells and
plasma IL-21 levels between IgAV patients and HC (a), between IgAV patients with different symptom types and HC (b). *P < 0.05, **P < 0.01,
compared with the HC group; NS, not significant, when compared with the HC group
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CXCR5+ICOShighPD-1high Tfh cells were dramatically el-
evated in patients with all symptom types; CXCR5+
CD45RA−IL-21+ Tfh cells were significantly higher in
patients with skin, abdominal, kidney and mixed types
(P < 0.001, 0.0011, 0.0008 and 0.0081, respectively), but
not in those with joint type (P > 0.05). Interestingly, CD4+
CXCR5+ICOS−PD-1+ Tfh cells was significantly lower in
patients with an abdominal type (P = 0.0412), but not in
those with other types (P > 0.05), compared with HC.
Furthermore, plasma IL-21 levels were significantly higher
in patients with skin and abdominal types (P = 0.0052 and
0.0027, respectively), but not in those with kidney, joint or
mixed type (P > 0.05), compared with HC.
When the association of different Tfh cells with treat-
ment options (non-GC vs. GC) were analyzed among
patients entering disease remission, no significant differ-
ence was detected in any of the Tfh cells or plasma IL-
21 (P > 0.05, data were not shown).
Alterations of Tfh cells and plasma IL-21 following
treatment
Following admission, all patients received symptom-
oriented and supportive therapies; and 25 patients
achieved disease remission. Among these patients, 15
patients were examined for these subpopulations of Tfh
cells before treatment during the active stage of the dis-
ease, as well as after treatment during the remission
stage (Fig. 3). With disease remission, the frequencies of
circulating CD4+CXCR5+ICOS+, CD4+CXCR5+ICOS+
PD-1+, CD4+CXCR5+ICOShighPD-1high and CXCR5+
CD45RA−IL-21+ Tfh cells were significantly reduced
from the corresponding value in the active stage (P =
0.0120, 0.0127, 0.0043 and 0.0290, respectively). No
significant difference was detected in CD4+CXCR5+
ICOS−PD-1+ cells following disease remission (P =
0.3375, Fig. 3). Meanwhile, plasma IL-21 levels also sig-
nificantly decreased in the remission stage, when com-
pared to the active stage (P = 0.0173, Fig. 3).
Correlation between Tfh cells and serum IgA, C4 and
plasma IL-21
When the correlation between different Tfh cells and differ-
ent clinical parameters of IgAV were analyzed, it was found
that circulating CXCR5+CD45RA−IL-21+ (r = 0.4371, P =
0.0255), CD4+CXCR5+ICOS+ Tfh cells (r = 0.5837, P =
0.0022), CD4+CXCR5+ICOS+PD-1+ (r = 0.3855, P = 0.0470)
and CD4+CXCR5+ICOShighPD-1high (r = 0.4849, P =
0.0104), but not CD4+CXCR5+ICOS−PD-1+ (r = −0.1618,
P = 0.4201, data were not shown) Tfh cells, were signifi-
cantly and positively correlated with serum IgA levels
(Fig. 4a-d). Circulating levels of CD4+CXCR5+ICOS+ (r =
0.6521, P = 0.0002), CD4+CXCR5+ICOS+PD-1+ (r =
0.4002, P = 0.0386) and CXCR5+CD45RA−IL-21+ (r =
0.5910, P = 0.0012) Tfh cells were also significantly and
positively correlated with plasma IL-21 levels (Fig. 4e-g).
Furthermore, circulating CXCR5+CD45RA−IL-21+ Tfh
cells (r = −0.3286, P = 0.0489) were the only cells signifi-
cantly and negatively correlated with serum C4 levels
(Fig. 4h).
Discussion
In this study, we presented prime evidence that circulat-
ing CD4+CXCR5+ Tfh cells are not homogenous, but ra-
ther a heterogeneous population of cells distinguishable
by combinations of Tfh phenotypic markers. Function-
ally, these phenotypic subpopulations are differentially
regulated in IgAV patients presenting different patterns
of association with the dominant symptoms of the dis-
ease, and un-equivalently correlated with key clinical
IgAV parameters. Upon disease remission following
treatment, these cells also responded differently. This is
the first study that revealed the differential contributions
of Tfh cells in IgAV pathogenesis and their alterations
following disease progression.
Consistent with their specialized functions to help B
cells in antibody production, the aberrant expansion of
Tfh cells have been identified in autoimmune diseases
including systemic lupus erythematosus (SLE), Sjogren’s
syndrome and juvenile dermatomyositis; which are all
characterized by the production of pathogenic autoanti-
bodies [25, 26]. Among the plethora of autoimmune dis-
eases, IgAV is a common connective tissue disease
associated with the vascular deposition of IgA-dominant
immunoglobulin complexes [1]. Most recently, scientists
began to investigate the potential involvement of Tfh
cells in IgAV, and two studies have both identified the
expansion of circulating CD4+CXCR5+ICOS+ Tfh cells
in IgAV patients, compared with cells in healthy controls
[22, 23]. However, neither these two nor other studies
explored the potential phenotypic subpopulations of Tfh
cells in IgAV or their association with different clinical
features of IgAV. Consistent with these two studies, we
have shown that the frequency of CD4+CXCR5+ICOS+
Tfh cells in peripheral blood from IgAV patients were
significantly higher than in healthy individuals. In
addition, we have revealed that the expansion was not
unique to CD4+CXCR5+ICOS+ cells, since the frequen-
cies of circulating CD4+CXCR5+, CD4+CXCR5+ICOS+
PD-1+, CD4+CXCR5+ICOShighPD-1high and CXCR5+
CD45RA−IL-21+ Tfh cells were also significantly higher
in IgAV patients. Furthermore, correlation studies re-
vealed that the frequencies of circulating CD4+CXCR5+
ICOS+, CD4+CXCR5+ICOS+PD-1+, CD4+CXCR5+
ICOShighPD-1high and CXCR5+CD45RA−IL-21+ Tfh
cells were significantly and positively correlated with
serum IgA levels. In contrast, the frequency of CD4+
CXCR5+ICOS−PD-1+ Tfh cells did not present any sig-
nificant change in IgAV patients, compared to healthy
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individuals, which is consistent with the findings of
Xie et al. [22]. Besides, CD4+CXCR5+ICOS−PD-1+ Tfh
cells were not correlated with serum IgA levels. These
data suggest that more than one phenotypic subpopu-
lations of Tfh cells, but not all, may contribute to the
pathogenesis and progression of IgAV.
Although not unique for Tfh cells, common Tfh cell
markers are closely associated with the functions of
these cells: chemokine receptor CXCR5 is important for
B-cell homing to B cell follicles [27, 28]; PD-1 supports
the survival and selection of high-affinity plasma cells in
the germinal center [29]; ICOS is essential for the
maintenance and function of Tfh in the germinal center
[30, 31]; IL-21 critically regulates the growth, differenti-
ation and class-switching of B cells [32, 33]. In circulat-
ing Tfh cells, the exact functions of each marker remains
to be addressed; but they may not significantly differ
from those in germinal center Tfh cells. All markers
were identified in CD4+CXCR5+ Tfh cells. However, it is
not known whether different combinations of these
markers would generate distinct subpopulations of Tfh
cells; and more importantly, whether these subpopula-
tions would be functionally different from each other. In
this study, we revealed that there are at least four differ-
ent phenotypic subpopulations of circulating Tfh cells:
CD4+CXCR5+ICOS+, CD4+CXCR5+ICOS+PD-1+, CD4+
CXCR5+ICOShighPD-1high, CD4+CXCR5+ICOS−PD-1+ and
CXCR5+CD45RA−IL-21+. Even though they may not be
completely exclusive from each other, they did present
varied biological functions in IgAV. CD4+CXCR5+ICOS+,
CD4+CXCR5+ICOS+PD-1+, CD4+CXCR5+ICOShighPD-
1high and CXCR5+CD45RA−IL-21+ Tfh cells were all
significantly expanded in the circulation of IgAV; and
their levels lowered dramatically following effective
treatment and disease remission. However, their fre-
quencies varied with the dominant clinical symptoms
presented in patients: CD4+CXCR5+ICOS+ cells were
not significantly altered in patients with predominant
Fig. 3 Treatment-induced alterations of different subpopulations of Tfh cells and plasma IL-21. After proper treatment, disease remission was
achieved in 15 patients. The frequency of the indicated Tfh cells and plasma IL-21 levels were compared between the active and remission stages
of the disease
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skin or joint symptoms; CXCR5+CD45RA−IL-21+ cells
were not significantly altered in patients with predom-
inant joint symptoms; both circulating CD4+CXCR5+
ICOS+PD-1+ and CD4+CXCR5+ICOShighPD-1high were
significantly expanded in IgA patients presenting with
all dominant symptoms, in which CD4+CXCR5+ICOS+
PD-1+ and CD4+CXCR5+ICOShighPD-1high were most
robustly expanded in patients with mixed symptoms,
as well as in CXCR5+CD45RA−IL-21+ cells in those
with skin symptoms. These findings imply that differ-
ent subpopulations of Tfh cells differentially regulate
the development of organ-specific symptoms.
Interestingly, although the frequency of circulating
CD4+CXCR5+ICOS−PD-1+ Tfh cells did not change
dramatically in IgAV patients compared to healthy indi-
viduals, their level was significantly lower in patients
presenting abdominal symptoms. PD-1 and its ligands
play a critical role in maintaining peripheral tolerance
[34]. Signaling through PD-1 attenuates the signaling
downstream of T cell receptors (TCR) and inhibits T cell
expansion, cytokine production and cytolytic activity. In
addition, PD-1 signaling inhibits the aberrant activation
of T cells and benefits the induction of regulatory T cells
[35–37]. The non-elevation of CD4+CXCR5+ICOS−PD-1+
Tfh cells in IgAV and its downregulation in patients pre-
senting abdominal dominant symptoms may reflect a
pathogenic mechanism during IgAV development, specif-
ically the development of abdominal symptoms in IgAV;
Fig. 4 Correlation between different phenotypic subpopulations of Tfh cells and serum IgA, complement C4 or plasma IL-21. The correlation
between the indicated Tfh cells and serum IgA (a-d), plasma IL-21 (e-g) and C4 (h) was analyzed by Pearson rank correlation test
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which would inhibit the potential immunosuppressive
activity of Tfh cells, and thus shift the balance toward
enhanced autoimmunity.
The characteristic cytokine produced by Tfh cells is
IL-21, which is a type I cytokine with pleiotropic im-
mune activities including regulating germinal center B-
cell responses, isotype switching and the generation of
memory B cells [38–40]. Both B and CD4+ T cells re-
quire IL-21 signaling for generating long-term humoral
immunity [17, 41]. Many CD4+ T cells can produce IL-
21, with the most abundant sources being Tfh and Th17
cells [42]. In this study, we found that plasma IL-21
levels were significantly elevated in IgAV patients, par-
ticularly in patients with dominant skin and abdominal
symptoms; but not in patients with joint, kidney or
mixed symptoms, as compared with healthy individuals.
Following disease remission, elevated plasma IL-21 level
was significantly reduced; suggesting that circulating IL-
21 levels are sensitive indicators for active IgAV.
Furthermore, we identified significant and positive cor-
relations between plasma IL-21 levels with the frequency
of circulating CXCR5+CD45RA−IL-21+, CD4+CXCR5+
ICOS+PD-1+ and CD4+CXCR5+ICOS+ Tfh cells, imply-
ing that these three phenotypes of Tfh cells may contrib-
ute to IgAV development through the secretion of IL-21.
GC is a powerful anti-inflammatory drug, but we only
use it for patients with severe symptoms. It can inhibit
inflammation by downregulating T and B cell function
and reducing cytokine production. In this study, we di-
vided patients during the remission stage (N = 15) into
the GC group (n = 5) and the non-GC group (n = 10).
Surprisingly, the difference in Tfh cell subsets between
these two groups was not significant. These findings also
supported the notion that IgAV is a common kind of
self-limiting disease, and its recovery is mainly based on
its own re-established immune homeostasis. Although
GC can rapidly relieve severe active symptoms, a small
dose of GC does not lead to immunosuppression, Cush-
ing’s syndrome, and other adverse reactions. In addition,
this result does not reflect the value of GC on immune
regulation due to the lack of long-term follow-up and
tracing studies; hence, we could not absolutely deter-
mine the value of GC therapy for IgAV, especially for
the long-term prognosis of renal type. The number of
patients in this study is few, and there is a need to ex-
plore more patients, especially with different prognosis
types, in future studies.
Although the major conclusions drawn from this study
are limited by the relatively small sample size, these provide
seminal findings that would guide future, larger-scale stud-
ies. Furthermore, it is important to further characterize the
Tfh cell subsets from this study, both on phenotypes and
functions; and compare them with Tfh cell subsets defined
from other studies such as Th1, Th2 and Th17 subsets [20].
In summary, this study identified multiple phenotypic
subpopulations of Tfh cells, namely, CD4+CXCR5+ICOS+,
CD4+CXCR5+ICOS+PD-1+, CD4+CXCR5+ICOShighPD-
1high, CD4+CXCR5+ICOS−PD-1+ and CXCR5+CD45RA−
IL-21+; which are functionally important for the pathogen-
esis of IgAV. The levels of these subpopulations in the
peripheral circulation of IgAV in patients were signifi-
cantly higher than in healthy individuals; they also correl-
ate with IgAV clinical markers including circulating IL-21
and IgA levels, which decreased following disease remis-
sion. In addition, these subsets presented differential
associations with the organ-specific symptoms of IgAV.
Therefore, these Tfh cells not only serve as indicators of
IgAV symptoms and progression, but also becomes thera-
peutic targets that enable the individualized or symptom-
oriented treatment of IgAV.
Conclusion
IgAV is the most common cutaneous vasculitis in children,
immune system disorders play a key role in its pathogen-
esis. Here, we found Tfh cells may differentially contribute
to the development of IgAV or predict disease progression.
These findings provide novel insights in the pathogenesis of
IgAV, and this may be new targets for intervention of
organ-specific IgAV.
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